The Kyoto Prognostic Index for Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era
Tsutomu Kobayashi(Kyoto first Red Cross hospital), Masafumi Taniwaki(Kyoto Prefectural University), Saeko Kuwahara(Kyoto first Red Cross hospital), Kazuna Tanba(Kyoto Prefectural University of Medicine), Isao Yokota(Kyoto University), Junya Kuroda(Kyoto Prefectural University of Medicine), Eri Kawata(Panasonic (Japan)), Satoshi Teramukai(Kyoto University Hospital), Yutaka Kobayashi(Gifu University), Teruaki Akaogi(Kyoto first Red Cross hospital), Reiko Isa(Kyoto Prefectural University of Medicine), Tomohiko Taki(Kyorin University), Takahiro Fujino(Kyoto University), Hiroto Kaneko, Hitoji Uchiyama(Japanese Red Cross Society Kyoto Daini Hospital), Junko Yamaguchi(Kyoto Prefectural University of Medicine), Nobuhiko Uoshima(Matsushita Memorial Hospital)
Cited by 3
Related Papers
Injection of Cultured Cells with a ROCK Inhibitor for Bullous Keratopathy
|New England Journal of Medicine|2018|551
Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion
|Proceedings of the National Academy of Sciences|2002|398